Key statistics
On Friday, Avalo Therapeutics Inc (C6K0:DEU) closed at 11.85, 26,529.21% above the 52 week low of 0.0445 set on Dec 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.00 |
---|---|
High | 12.10 |
Low | 11.50 |
Bid | 11.50 |
Offer | 12.55 |
Previous close | 11.70 |
Average volume | 15.00 |
---|---|
Shares outstanding | 9.68m |
Free float | 8.80m |
P/E (TTM) | -- |
Market cap | 128.87m USD |
EPS (TTM) | -63.82 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Announcements
- Avalo Therapeutics to Present at Upcoming Investor Conferences
- Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
- Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
- Avalo Announces Participation in September Investor Conferences
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
More ▼